The American Journal of Managed Care

Subcutaneous Treatments Can Save Chair Time, Decrease Infusion Reaction in NSCLC: Joshua K. Sabari, MD

Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment ...
The American Journal of Managed Care

FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease

Onapgo, a subcutaneous apomorphine infusion device, is approved for advanced Parkinson's disease, offering continuous symptom management without surgery. The TOLEDO trial showed apomorphine infusion ...
MedPage Today

Continuous Parkinson's Disease Therapy Wins FDA Nod

Foscarbidopa and foslevodopa are pro-drugs for carbidopa and levodopa, which are standard-of-care Parkinson's treatments. The new treatment, formerly know as ABBV-951, is the first subcutaneous ...
Medscape

FDA OKs Novel Levodopa-Based Continuous Sub-Q Regimen for Parkinson’s

The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for ...
Healio

FDA approves Vyalev for motor fluctuations in advanced Parkinson’s disease

The FDA has approved Vyalev, a continuous, subcutaneous 24-hour infusion, to address motor fluctuations in adults with advanced Parkinson's disease, according to the manufacturer. The approval was ...